Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577352 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
A Phase 2 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT04577352 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 146 participants.
The verdict
NCT04577352, a Phase 2 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale \[mFARS\]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
Interventions
- DRUG Placebo
- DRUG Vatiquinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2020-12-17 |
| Est. Completion | 2023-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04577352
The ClinicalTrials.gov registry entry for NCT04577352 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04577352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04577352 about?
NCT04577352 is a clinical study titled "A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia". The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale \[mFARS\]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
What is the current status of trial NCT04577352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2020-12-17. Estimated completion is 2023-10-02.
What interventions are being tested in trial NCT04577352?
The interventions under investigation include: Placebo (DRUG), Vatiquinone (DRUG).
Who is sponsoring clinical trial NCT04577352?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.